Is AKTS or IFRX more profitable?

Aktis Oncology's return on equity of 0.00% beat InflaRx's return on equity. Company Net Margins Return on Equity Return on Assets Aktis Oncology N/A N/A N/A InflaRx N/A -53.56% -43.02%

Does the media prefer AKTS or IFRX?

In the previous week, InflaRx had 4 more articles in the media than Aktis Oncology. MarketBeat recorded 6 mentions for InflaRx and 2 mentions for Aktis Oncology. Aktis Oncology's average media sentiment score of 0.86 beat InflaRx's score of 0.39 indicating that Aktis Oncology is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Aktis Oncology 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive InflaRx 1 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has higher earnings and valuation, IFRX or IMTX?

InflaRx has higher earnings, but lower revenue than Immatics. Immatics is trading at a lower price-to-earnings ratio than InflaRx, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio InflaRx $30K 10,291.34 -$51.63M -$0.58 N/A Immatics $54.60M 21.58 -$222.26M -$1.86 N/A

Is IFRX or IMTX more profitable?

InflaRx has a net margin of 0.00% compared to Immatics' net margin of -495.71%. Immatics' return on equity of -47.41% beat InflaRx's return on equity. Company Net Margins Return on Equity Return on Assets InflaRx N/A -53.56% -43.02% Immatics -495.71% -47.41% -39.45%

Does the media prefer IFRX or IMTX?

In the previous week, InflaRx had 4 more articles in the media than Immatics. MarketBeat recorded 6 mentions for InflaRx and 2 mentions for Immatics. Immatics' average media sentiment score of 1.02 beat InflaRx's score of 0.39 indicating that Immatics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment InflaRx 1 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Immatics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is ODTX or IFRX more profitable?

Odyssey Therapeutics' return on equity of 0.00% beat InflaRx's return on equity. Company Net Margins Return on Equity Return on Assets Odyssey Therapeutics N/A N/A N/A InflaRx N/A -53.56% -43.02%

Does the media prefer ODTX or IFRX?

In the previous week, InflaRx had 4 more articles in the media than Odyssey Therapeutics. MarketBeat recorded 6 mentions for InflaRx and 2 mentions for Odyssey Therapeutics. Odyssey Therapeutics' average media sentiment score of 0.48 beat InflaRx's score of 0.39 indicating that Odyssey Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Odyssey Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral InflaRx 1 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has higher valuation & earnings, MNKD or IFRX?

MannKind has higher revenue and earnings than InflaRx. MannKind is trading at a lower price-to-earnings ratio than InflaRx, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio MannKind $348.97M 3.26 $5.86M -$0.13 N/A InflaRx $30K 10,291.34 -$51.63M -$0.58 N/A

Is MNKD or IFRX more profitable?

InflaRx has a net margin of 0.00% compared to MannKind's net margin of -11.08%. MannKind's return on equity of -11.21% beat InflaRx's return on equity. Company Net Margins Return on Equity Return on Assets MannKind -11.08% -11.21% -6.31% InflaRx N/A -53.56% -43.02%

Does the media refer more to MNKD or IFRX?

In the previous week, MannKind had 5 more articles in the media than InflaRx. MarketBeat recorded 11 mentions for MannKind and 6 mentions for InflaRx. MannKind's average media sentiment score of 0.45 beat InflaRx's score of 0.39 indicating that MannKind is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment MannKind 5 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral InflaRx 1 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has preferable valuation & earnings, SVRA or IFRX?

InflaRx has higher revenue and earnings than Savara. Savara is trading at a lower price-to-earnings ratio than InflaRx, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Savara N/A N/A -$118.84M -$0.58 N/A InflaRx $30K 10,291.34 -$51.63M -$0.58 N/A

Is SVRA or IFRX more profitable?

InflaRx's return on equity of -53.56% beat Savara's return on equity. Company Net Margins Return on Equity Return on Assets Savara N/A -90.28% -68.95% InflaRx N/A -53.56% -43.02%

Does the media favor SVRA or IFRX?

In the previous week, InflaRx had 5 more articles in the media than Savara. MarketBeat recorded 6 mentions for InflaRx and 1 mentions for Savara. Savara's average media sentiment score of 1.02 beat InflaRx's score of 0.39 indicating that Savara is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Savara 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive InflaRx 1 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

InflaRx (IFRX) Competitors

$2.10 +0.04 (+1.70%)

Closing price 09/18/2026 03:59 PM Eastern

Extended Trading

$2.08 -0.01 (-0.67%)

As of 09/18/2026 07:30 PM Eastern

Compare

IFRX vs. AKTS, IMTX, ODTX, MNKD, and SVRA

Should you buy InflaRx stock or one of its competitors? InflaRx's main competitors and comparable companies include Aktis Oncology (AKTS), Immatics (IMTX), Odyssey Therapeutics (ODTX), MannKind (MNKD), and Savara (SVRA). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does InflaRx compare to Aktis Oncology?

Aktis Oncology (NASDAQ:AKTS) and InflaRx (NASDAQ:IFRX) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, dividends, profitability, earnings, media sentiment, valuation and risk.

In the previous week, InflaRx had 4 more articles in the media than Aktis Oncology. MarketBeat recorded 6 mentions for InflaRx and 2 mentions for Aktis Oncology. Aktis Oncology's average media sentiment score of 0.86 beat InflaRx's score of 0.39 indicating that Aktis Oncology is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Aktis Oncology	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
InflaRx	1 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

InflaRx has lower revenue, but higher earnings than Aktis Oncology. Aktis Oncology is trading at a lower price-to-earnings ratio than InflaRx, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aktis Oncology	$6.50M	180.93	-$63.73M	-$0.82	N/A
InflaRx	$30K	10,291.34	-$51.63M	-$0.58	N/A

28.8% of Aktis Oncology shares are owned by institutional investors. Comparatively, 42.4% of InflaRx shares are owned by institutional investors. 3.3% of Aktis Oncology shares are owned by insiders. Comparatively, 16.3% of InflaRx shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Aktis Oncology currently has a consensus target price of $35.63, suggesting a potential upside of 62.82%. InflaRx has a consensus target price of $7.43, suggesting a potential upside of 254.59%. Given InflaRx's higher possible upside, analysts plainly believe InflaRx is more favorable than Aktis Oncology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aktis Oncology	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.91
InflaRx	1 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.67

Aktis Oncology's return on equity of 0.00% beat InflaRx's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aktis Oncology	N/A	N/A	N/A
InflaRx	N/A	-53.56%	-43.02%

Summary

InflaRx beats Aktis Oncology on 8 of the 14 factors compared between the two stocks.

How does InflaRx compare to Immatics?

InflaRx (NASDAQ:IFRX) and Immatics (NASDAQ:IMTX) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, risk, dividends, media sentiment, valuation, institutional ownership, profitability and analyst recommendations.

42.4% of InflaRx shares are owned by institutional investors. Comparatively, 64.4% of Immatics shares are owned by institutional investors. 16.3% of InflaRx shares are owned by insiders. Comparatively, 3.3% of Immatics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

InflaRx currently has a consensus target price of $7.43, suggesting a potential upside of 254.59%. Immatics has a consensus target price of $20.60, suggesting a potential upside of 138.98%. Given InflaRx's stronger consensus rating and higher probable upside, equities analysts clearly believe InflaRx is more favorable than Immatics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
InflaRx	1 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.67
Immatics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63

InflaRx has a net margin of 0.00% compared to Immatics' net margin of -495.71%. Immatics' return on equity of -47.41% beat InflaRx's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
InflaRx	N/A	-53.56%	-43.02%
Immatics	-495.71%	-47.41%	-39.45%

InflaRx has higher earnings, but lower revenue than Immatics. Immatics is trading at a lower price-to-earnings ratio than InflaRx, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
InflaRx	$30K	10,291.34	-$51.63M	-$0.58	N/A
Immatics	$54.60M	21.58	-$222.26M	-$1.86	N/A

In the previous week, InflaRx had 4 more articles in the media than Immatics. MarketBeat recorded 6 mentions for InflaRx and 2 mentions for Immatics. Immatics' average media sentiment score of 1.02 beat InflaRx's score of 0.39 indicating that Immatics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
InflaRx	1 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Immatics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

InflaRx has a beta of 2.52, suggesting that its share price is 152% more volatile than the broader market. Comparatively, Immatics has a beta of 1.33, suggesting that its share price is 33% more volatile than the broader market.

Summary

InflaRx beats Immatics on 11 of the 17 factors compared between the two stocks.

How does InflaRx compare to Odyssey Therapeutics?

Odyssey Therapeutics (NASDAQ:ODTX) and InflaRx (NASDAQ:IFRX) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, media sentiment, valuation, profitability, risk, analyst recommendations, dividends and institutional ownership.

Odyssey Therapeutics currently has a consensus price target of $35.75, indicating a potential upside of 46.64%. InflaRx has a consensus price target of $7.43, indicating a potential upside of 254.59%. Given InflaRx's stronger consensus rating and higher probable upside, analysts clearly believe InflaRx is more favorable than Odyssey Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Odyssey Therapeutics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63
InflaRx	1 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.67

Odyssey Therapeutics has higher earnings, but lower revenue than InflaRx. InflaRx is trading at a lower price-to-earnings ratio than Odyssey Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Odyssey Therapeutics	N/A	N/A	N/A	-$6.77	N/A
InflaRx	$30K	10,291.34	-$51.63M	-$0.58	N/A

Odyssey Therapeutics' return on equity of 0.00% beat InflaRx's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Odyssey Therapeutics	N/A	N/A	N/A
InflaRx	N/A	-53.56%	-43.02%

42.4% of InflaRx shares are held by institutional investors. 16.3% of InflaRx shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

In the previous week, InflaRx had 4 more articles in the media than Odyssey Therapeutics. MarketBeat recorded 6 mentions for InflaRx and 2 mentions for Odyssey Therapeutics. Odyssey Therapeutics' average media sentiment score of 0.48 beat InflaRx's score of 0.39 indicating that Odyssey Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Odyssey Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
InflaRx	1 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

InflaRx beats Odyssey Therapeutics on 8 of the 13 factors compared between the two stocks.

How does InflaRx compare to MannKind?

MannKind (NASDAQ:MNKD) and InflaRx (NASDAQ:IFRX) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, valuation, media sentiment, analyst recommendations, profitability, earnings, dividends and institutional ownership.

InflaRx has a net margin of 0.00% compared to MannKind's net margin of -11.08%. MannKind's return on equity of -11.21% beat InflaRx's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MannKind	-11.08%	-11.21%	-6.31%
InflaRx	N/A	-53.56%	-43.02%

MannKind currently has a consensus target price of $8.34, indicating a potential upside of 135.70%. InflaRx has a consensus target price of $7.43, indicating a potential upside of 254.59%. Given InflaRx's stronger consensus rating and higher probable upside, analysts clearly believe InflaRx is more favorable than MannKind.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MannKind	2 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.50
InflaRx	1 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.67

In the previous week, MannKind had 5 more articles in the media than InflaRx. MarketBeat recorded 11 mentions for MannKind and 6 mentions for InflaRx. MannKind's average media sentiment score of 0.45 beat InflaRx's score of 0.39 indicating that MannKind is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
MannKind	5 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
InflaRx	1 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

MannKind has higher revenue and earnings than InflaRx. MannKind is trading at a lower price-to-earnings ratio than InflaRx, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MannKind	$348.97M	3.26	$5.86M	-$0.13	N/A
InflaRx	$30K	10,291.34	-$51.63M	-$0.58	N/A

MannKind has a beta of 1.1, suggesting that its stock price is 10% more volatile than the broader market. Comparatively, InflaRx has a beta of 2.52, suggesting that its stock price is 152% more volatile than the broader market.

49.6% of MannKind shares are owned by institutional investors. Comparatively, 42.4% of InflaRx shares are owned by institutional investors. 2.6% of MannKind shares are owned by insiders. Comparatively, 16.3% of InflaRx shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Summary

MannKind beats InflaRx on 9 of the 17 factors compared between the two stocks.

How does InflaRx compare to Savara?

Savara (NASDAQ:SVRA) and InflaRx (NASDAQ:IFRX) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their earnings, analyst recommendations, dividends, valuation, risk, profitability, institutional ownership and media sentiment.

InflaRx's return on equity of -53.56% beat Savara's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Savara	N/A	-90.28%	-68.95%
InflaRx	N/A	-53.56%	-43.02%

87.9% of Savara shares are owned by institutional investors. Comparatively, 42.4% of InflaRx shares are owned by institutional investors. 5.3% of Savara shares are owned by insiders. Comparatively, 16.3% of InflaRx shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Savara currently has a consensus target price of $10.00, indicating a potential upside of 86.22%. InflaRx has a consensus target price of $7.43, indicating a potential upside of 254.59%. Given InflaRx's higher probable upside, analysts plainly believe InflaRx is more favorable than Savara.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Savara	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88
InflaRx	1 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.67

In the previous week, InflaRx had 5 more articles in the media than Savara. MarketBeat recorded 6 mentions for InflaRx and 1 mentions for Savara. Savara's average media sentiment score of 1.02 beat InflaRx's score of 0.39 indicating that Savara is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Savara	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
InflaRx	1 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

InflaRx has higher revenue and earnings than Savara. Savara is trading at a lower price-to-earnings ratio than InflaRx, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Savara	N/A	N/A	-$118.84M	-$0.58	N/A
InflaRx	$30K	10,291.34	-$51.63M	-$0.58	N/A

Savara has a beta of 0.25, meaning that its stock price is 75% less volatile than the broader market. Comparatively, InflaRx has a beta of 2.52, meaning that its stock price is 152% more volatile than the broader market.

Summary

InflaRx beats Savara on 9 of the 13 factors compared between the two stocks.

Get InflaRx News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding IFRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

IFRX vs. The Competition

Export

Metric	InflaRx	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$308M	$3.89B	$7.24B	$13.19B
Dividend Yield	N/A	3.64%	2.57%	12.81%
P/E Ratio	-3.61	14.23	275.49	25.40
Price / Sales	10,291.34	1,419.61	646.01	89.45
Price / Cash	N/A	108.90	76.25	51.42
Price / Book	3.22	15.45	10.46	6.33
Net Income	-$51.63M	-$22.86M	$3.49B	$358.33M
7 Day Performance	0.24%	-1.21%	0.59%	1.12%
1 Month Performance	3.71%	-3.29%	-1.74%	-2.39%
1 Year Performance	56.34%	37.74%	18.13%	5.35%

InflaRx Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
IFRX InflaRx	2.0751 of 5 stars	$2.10 +1.7%	$7.43 +254.6%	+56.3%	$308M	$30K	N/A	65
AKTS Aktis Oncology	3.0429 of 5 stars	$22.56 -1.3%	$35.63 +57.9%	N/A	$1.21B	$10.06M	N/A	79
IMTX Immatics	3.2686 of 5 stars	$8.59 -2.6%	$20.60 +139.9%	+28.7%	$1.17B	$41.70M	N/A	704	Positive News
ODTX Odyssey Therapeutics	2.8792 of 5 stars	$24.28 +4.6%	$35.75 +47.2%	N/A	$1.17B	N/A	N/A	100
MNKD MannKind	2.9602 of 5 stars	$3.55 -1.0%	$8.34 +135.4%	-34.8%	$1.14B	$348.97M	N/A	592

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:IFRX) was last updated on 9/20/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

InflaRx (IFRX) Competitors

IFRX vs. AKTS, IMTX, ODTX, MNKD, and SVRA

How does InflaRx compare to Aktis Oncology?

Summary

How does InflaRx compare to Immatics?

Summary

How does InflaRx compare to Odyssey Therapeutics?

Summary

How does InflaRx compare to MannKind?

Summary

How does InflaRx compare to Savara?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IFRX vs. The Competition

InflaRx Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

InflaRx (IFRX) Competitors

IFRX vs. AKTS, IMTX, ODTX, MNKD, and SVRA

How does InflaRx compare to Aktis Oncology?

Does the media prefer AKTS or IFRX?

Which has preferable earnings & valuation, AKTS or IFRX?

Do insiders & institutionals hold more shares of AKTS or IFRX?

Do analysts rate AKTS or IFRX?

Is AKTS or IFRX more profitable?

Summary

How does InflaRx compare to Immatics?

Do insiders and institutionals have more ownership in IFRX or IMTX?

Do analysts recommend IFRX or IMTX?

Is IFRX or IMTX more profitable?

Which has higher earnings and valuation, IFRX or IMTX?

Does the media prefer IFRX or IMTX?

Which has more risk and volatility, IFRX or IMTX?

Summary

How does InflaRx compare to Odyssey Therapeutics?

Do analysts prefer ODTX or IFRX?

Which has better valuation and earnings, ODTX or IFRX?

Is ODTX or IFRX more profitable?

Do insiders & institutionals believe in ODTX or IFRX?

Does the media prefer ODTX or IFRX?

Summary

How does InflaRx compare to MannKind?

Is MNKD or IFRX more profitable?

Do analysts rate MNKD or IFRX?

Does the media refer more to MNKD or IFRX?

Which has higher valuation & earnings, MNKD or IFRX?

Which has more volatility and risk, MNKD or IFRX?

Do insiders and institutionals believe in MNKD or IFRX?

Summary

How does InflaRx compare to Savara?

Is SVRA or IFRX more profitable?

Do institutionals and insiders hold more shares of SVRA or IFRX?

Do analysts prefer SVRA or IFRX?

Does the media favor SVRA or IFRX?

Which has preferable valuation & earnings, SVRA or IFRX?

Which has more risk & volatility, SVRA or IFRX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IFRX vs. The Competition

InflaRx Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools